

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

For the month of **July 2021**

**Commission File Number: 001-40106**

**4D pharma plc**

*(Translation of Registrant's name into English)*

**5th Floor, 9 Bond Court  
Leeds  
LS1 2JZ  
United Kingdom  
Tel: +44 (0) 113 895 013**

*(Address of principal executive offices)*

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

---

---

### **Announcement of Passing of Chief Financial Officer**

On July 26, 2021, 4D pharma plc (the “Company”) issued a press release to announce the passing of John Beck, the Company’s Chief Financial Officer.

“We are deeply saddened by John’s passing. The entire 4D pharma community mourns this loss and, on behalf of our Board of Directors and employees, we extend our sincerest condolences to his family,” said Duncan Peyton, Chief Executive Officer of the Company. “John’s 30 years of experience in the financial and biopharmaceutical industries were invaluable to us in his role as Chief Financial Officer, and his vision for the future of 4D pharma was already well on its way to being realized. We grieve this loss and will carry his legacy forward in this next chapter of 4D pharma’s continued growth and progress.”

The Company will continue to be actively led by its current management team and Board of Directors and succession planning is underway.

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**4D pharma plc**

Date: July 27, 2021

*/s/ Duncan Peyton*

---

Duncan Peyton  
Chief Executive Officer

---

INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Exhibit Title</b>
99.1	<a href="#">Press Release, dated July 26, 2021.</a>



4D pharma PLC

### **4D pharma Announces Passing of Chief Financial Officer John Beck**

**Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS)**, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces with great sadness that John Beck, Chief Financial Officer of 4D pharma, has passed away.

“We are deeply saddened by John’s passing. The entire 4D pharma community mourns this loss and, on behalf of our Board of Directors and employees, we extend our sincerest condolences to his family,” said Duncan Peyton, Chief Executive Officer of 4D pharma. “John’s 30 years of experience in the financial and biopharmaceutical industries were invaluable to us in his role as Chief Financial Officer, and his vision for the future of 4D pharma was already well on its way to being realized. We grieve this loss and will carry his legacy forward in this next chapter of 4D pharma’s continued growth and progress.”

4D pharma will continue to be actively led by its current management team and Board of Directors and succession planning is underway.

#### **About 4D pharma**

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma’s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson’s disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to <https://www.4dpharmapl.com>

#### **Contact Information:**

##### **4D pharma**

Investor Relations: [ir@4dpharmapl.com](mailto:ir@4dpharmapl.com)

---



4D pharma PLC

**N+1 Singer - Nominated Adviser and Joint Broker** +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

**Bryan Garnier & Co. Limited - Joint Broker** +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

**Stern Investor Relations, Inc.** +1-212-362-1200

Julie Seidel [Julie.seidel@sternir.com](mailto:Julie.seidel@sternir.com)

**Image Box Communications** +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

[neil@ibcomms.agency](mailto:neil@ibcomms.agency) / [michelle@ibcomms.agency](mailto:michelle@ibcomms.agency)

---